Tests eptinezumab to prevent long-lasting headaches after head injury
Tests an early infusion of eptinezumab in adults with migraine-like headaches after mild brain injury.
Plain-language title generated from the registry record
Registry title: Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT)
Key facts
- Where
- Toronto, CanadaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who developed acute headache after a mild head injury, within 8 weeks of the headache starting. It tests eptinezumab against placebo.
- Age
- 18 Years to 65 Years
- Sex
- All
- Disease stage
- Acute post-traumatic headache (ICHD-3 criteria) within 8 weeks of onset. Migraine screening score (MSQ) of 4 or more in at least one weekly screening call.
- Earlier treatment
- No CGRP-related treatment or botulinum toxin for migraine in the last three months.
Main reasons for not taking part
- Moderate to severe traumatic brain injury
- Mild traumatic brain injury in the past 5 years
- Chronic migraine, tension-type headache or other headache disorders before the injury
- Substance or opioid use disorder
- Pregnancy or breast-feeding
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07191145, who can take part
Where in Canada
- Sunnybrook Health Sciences CentreToronto, CanadaContact: Howard Meng, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Sunnybrook Health Sciences Centre
- Trial code
- NCT07191145
- Record updated
- 29 October 2026
- Original description
Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting > 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.Read full original descriptionShow less
EarLy Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT): a Parallel Group, Randomized, Double Blind, Placebo Controlled Trial
Most individuals with mild traumatic brain injury (mTBI) experience post-traumatic headaches (PTH). Of PTH, 50% present with a migraine phenotype which is the most disabling type of PTH. Patients with migraine-PTH are at greater risk of persistent symptoms whereby the acute PTH (aPTH) becomes persistent PTH (pPTH) (ie. lasting > 3 months) with a conversion rate of 47-95%. As migraine symptoms become chronic, it becomes treatment resistant. Despite these implications, early preventive medication management of PTH is marred by lengthy trials of multiple medications (2-3 months for each) and adverse effects that aggravate mTBI symptoms (fatigue, nausea, and presyncope). There is a compelling need to establish an effective treatment to prevent this debilitating outcome. Eptinezumab is a calcitonin gene-related peptide (CGRP)-blocking monoclonal antibody that reduces migraine burden in patients with migraines after a single infusion. Patients with PTH have higher serum levels of CGRP and experimental infusion of CGRP to patients with mTBI reproduces migraine PTH symptoms. Given the similarly in CGRP expression between chronic migraines and PTH, an infusion of eptinezumab within 8 weeks of PTH is hypothesized to reduce headache burden 3 months after treatment and prevent pPTH.
Inclusion: Meet diagnostic criteria for acute post-traumatic headache as per ICHD-3 criteria; Meet migraine screening questionnaire criteria (MSQ score ≥ 4) during at least one of the weekly screening calls; Within 8 weeks after onset of PTH; Imaging is not required for inclusion; Negative human chorionic gonadotropin test before treatment, for female participants of childbearing potential who are not practicing medically appropriate methods of birth control (e.g., hormonal contraceptives, implants, injectables, intrauterine devices, intrauterine systems, etc.).
Exclusion: Concurrent use of CGRP-related treatment or botulinum toxin within the last three month for migraine; Concurrent major injuries (long bone, rib, and spinal fractures) or surgical intervention while in hospital on initial trauma; History of mTBI within the past 5 years; Pre-existing chronic migraine and its subtypes, tension-type headache, trigeminal autonomic cephalalgias, cranial neuralgias, daily headache, diagnosis of another secondary headache disorder per ICHD-3 (except medication overuse headache); Substance / opioids use disorder; Confounding chronic pain disorder / clinically significant pains; Uncontrolled psychiatric conditions (depression, PTSD, anxiety, functional neurological disorder); Diagnosis of moderate to severe TBI; On-going litigation for current trauma; Pregnancy/breast-feeding; Use of opioids/barbiturates for headaches (> 4 days/month); Hereditary fructose intolerance.